Infection, Respiratory Tract
Conditions
Keywords
infectious respiratory diseases
Brief summary
The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic . VPM1002 is a vaccine that is a further development of the old Bacillus Calmette-Guérin (BCG) vaccine, which has been used successfully as a vaccine against tuberculosis for about 100 years, especially in developing countries. VPM1002 has been shown in various clinical studies to be significantly safer than the BCG vaccine. VPM1002 strengthens the body's immune defence and vaccination with BCG reduces the frequency of respiratory diseases. It is therefore assumed that a VPM1002 vaccination could also provide (partial) protection against COVID-19 disease caused by the new corona virus SARS-CoV 2.
Detailed description
Based on the evidence that BCG \[Bacille Calmette-Guérin\] vaccine 1. can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity, and 2. can reduce the incidence of respiratory infections, exert antiviral effects in experimental models, and reduce viremia in an experimental human model of viral infection, it is hypothesized that BCG vaccination may induce (partial) protection against the susceptibility to and/or severity of SARS-CoV-2 infections. VPM1002 is being developed with the aim to replace BCG by a vaccine that has a better safety profile and superior efficacy. Evidence from pre-clinical and clinical studies demonstrate that VPM1002 is safer and is more immunogenic than the existing BCG vaccine (for more information, please revert to the IB). It is therefore anticipated that VPM1002 will also perform better in reducing the severity of the symptoms of an infection with the SARS-CoV-2 than the BCG vaccine. Further, manufacturing of VPM1002 using state-of-the-art production methods will help hasten the production of millions of doses in a very short time and thus would be beneficial in the current SARS-CoV-2 pandemic situation. The current trial will assess the efficacy and safety of VPM1002 to reduce the hospital admissions and clinical consequences of SARS-CoV-2 infections in the elderly population in the SARS-CoV-2 pandemic by modulating the immune system. A total of 2038 adults aged 60 or above will be enrolled across involved clinical trial sites in Germany. Informed consent will be obtained from the subjects willing to take part in the trial. This will be followed by assessment of the eligibility criteria. Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo. All subjects will be requested to sign into a web-based tool designed for this trial. Every subject is encouraged to name a designated caregiver who may provide follow-up data in case of hospitalisation or severe illness of the study subject. All subjects will be followed-up entirely remotely. The questionnaires will be designed to collect data regarding hospitalisation, adverse events (AE)/serious adverse events (SAE), ICU admissions and other secondary endpoints. The investigators will review the outcome and safety data. The duration of follow-up will be 240 days. Subjects with confirmed SARS-CoV-2 infection (with or without symptoms) will be followed for at least 6 weeks (from the date of test result), independent of the total trial duration.
Interventions
BIOLOGICALVPM1002
The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
BIOLOGICALPlacebo
The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Sponsors
FGK Clinical Research GmbH
Serum Life Science Europe GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
The reconstitution of trial intervention will be done by unblinded site personnel who will not be involved in the collection or evaluation of outcome data. Administration of the trial intervention will be done by blinded site personnel.
Intervention model description
Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo.
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male or female adult (≥ 60 years) 2. Subject is contractually capable, able to understand information on study and has signed informed consent sheet 3. Subject has access to an internet-enabled electronic device
Exclusion criteria
1. Known active or latent Mycobacterium tuberculosis infection 2. Fever (\> 38 °C) or respiratory tract infection within the past 24 hours 3. Current active viral or bacterial infection 4. Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination 5. Participation in another interventional study within 30 days before screening and during this study 6. Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Guérin (BCG) administration 7. Severely immunocompromised subjects, including: 1. subjects with known infection by the human immunodeficiency virus (HIV-1); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy, or radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks; 8. History of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial 9. Previous positive SARS-CoV-2 test result 10. Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of days with severe respiratory disease at hospital and/or at home | From day 0 to day 240 |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of hospital admissions | From day 0 to day 240 |
| Cumulative incidence of documented SARS-CoV-2 infection | From day 0 to day 240 |
| Number of days with self-reported fever (≥ 38 ºC) | From day 0 to day 240 |
| Number of days with self-reported acute respiratory symptoms | From day 0 to day 240 |
| Cumulative incidence of self-reported acute respiratory symptoms | From day 0 to day 240 |
| Cumulative incidence of death for any reason | From day 0 to day 240 |
| Cumulative incidence of death due to documented SARS-CoV-2 infection | From day 0 to day 240 |
| Cumulative incidence of ICU admission for any reason | From day 0 to day 240 |
| Cumulative incidence of ICU admission due to documented SARS-CoV-2 infection | From day 0 to day 240 |
| Cumulative incidence of hospital admission due to documented SARSCoV- 2 infection | From day 0 to day 240 |
Countries
Germany
Outcome results
None listed